Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 158,18 € (+22,37%). La mediana è 157,51 € (+21,86%).
| Acquista |
26 |
| Mantieni |
0 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
Protagonist Therapeutics after approvals: over $1 billion cash, $300 million buyback and broad oral pipeline
Protagonist Therapeutics sees its peptide platform validated by the approvals of Icotrokinra and MIMRYLO/Rusfertide and reports a pro-forma cash balance of over $1 billion following a $275 million milestone payment. Management announced a $300 million share repurchase program but emphasized that research and development remain the highest priority. The company is advancing several oral programs (IL‑23/IL‑17/IL‑4, obesity triple agonist) and is selectively seeking partnerships for late-stage development and commercialization. » Altro su de.investing.com
Protagonist Therapeutics announces $300 million share buyback and plans to use licensing revenue to fund pipeline
At the Citigroup Biopharma Summit, Protagonist Therapeutics highlighted its shift to a commercial phase after two approvals and reported strong launch data for ICOTYDE and positive data for MIMRYLO (Rusfertide). The company plans a $300 million share repurchase program and intends to use future licensing income to finance R&D and enhance shareholder returns. The pipeline focuses on oral peptide therapeutics in immunology, obesity and rare diseases, with Protagonist seeking early partnerships and aiming to advance programs to proof-of-concept. Near-term success and valuation depend on sustained sales of the approved products, progress of the oral candidates and favourable partnerships. » Altro su de.investing.com
Protagonist Therapeutics approves $300 million share buyback program
The board of directors of Protagonist Therapeutics has approved a share buyback program of up to $300 million, to be funded from cash on hand, cash equivalents, marketable securities and license and collaboration payments. As of June 30, 2026, the company had $849.5 million in cash; additional payments from Takeda totaling $275 million are expected in Q4 2026. The timing and amount of repurchases will depend on market conditions, the share price and license and milestone payments; the program does not obligate the company to buy any specific number of shares. Protagonist generates revenue from royalties under partnerships for MIMRYLO (Rusfertide) with Takeda and ICOTYDE (Icotrokinra) with Johnson & Johnson. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giugno 2026 | YoY |
|---|---|---|
| Ricavi | 187,05 Mln | 3875,25% |
| Utile lordo | 187,05 Mln | 3875,25% |
| Utile netto | 142,69 Mln | 583,69% |
| EBITDA | 145,02 Mln | 598,42% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 8,36 Mld € |
Numero di azioni | 64,71 Mln |
Massimo/minimo a 52 settimane | 143,51 € - 67,32 € |
| Dividendi | No |
Beta | 1,79 |
Rapporto P/E | 118,85 |
Rapporto PEG | -0,14 |
Rapporto P/B | 11,34 |
Rapporto P/S | 33,22 |
Profilo aziendale
Protagonist Therapeutics, Inc., una società biofarmaceutica, scopre e sviluppa farmaci terapeutici a base di peptidi per affrontare l'ematologia e i disturbi del sangue, nonché le malattie infiammatorie e immunomodulatorie. Sta sviluppando rusfertide (PTG-300), un mimetico dell'epcidina iniettabile che si trova in fase II di sperimentazione clinica per il trattamento di pazienti con policitemia vera ed emocromatosi ereditaria, nonché per il trattamento di altri disturbi del sangue; PN-943, un peptide antagonista orale specifico per l'integrina alfa-4-beta-7 che si trova in fase II di sperimentazione clinica per il trattamento della malattia infiammatoria intestinale (IBD); e PN-235, un antagonista orale specifico del recettore dell'interleuchina-23 per il trattamento dell'IBD e di indicazioni non IBD. La società ha un accordo di licenza e collaborazione con Janssen Biotech, Inc. Protagonist Therapeutics, Inc. è stata costituita nel 2006 ed ha sede a Newark, California.
| Nome | Protagonist Therapeutics |
| CEO | Dinesh V. Patel |
| Sede centrale | Newark,
ca Stati Uniti |
| Sito web | |
| Settore | Materiali |
| Industria | Prodotti chimici |
| Quotazione in borsa | 11/08/2016 |
| Dipendenti | 141 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | PTGX |
